Crispr Therapeutics
在场
Crispr Therapeutics 是一家在股票代码 CRSP (CH) 下上市的公司。
高管
查看带有其 18 名主要高管的组织结构图
Crispr Therapeutics 搜索最多的简介
- Samarth Kulkarni, Chief Executive Officer and Chairman of the Board
- Simeon George, Director
- Edd Fleming, Director
高管在Crispr Therapeutics变化
- Naimish Patel已作为Chief Medical Officer加入公司 (新闻发布的2024五月24号).
- Julianne Bruno 曾任 Senior Vice President and Head of Programs & Portfolio Management, 现升职为 Chief Operating Officer (新闻发布的2024五月24号).
创建提醒
跟踪 Crispr Therapeutics 的高管变动
生物技术
Crispr Therapeutics 拥有 2,333 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Visus Therapeutics and Tenpoint Therapeutics have merged (公布2024十二月27号)..
- Deerfield has announced the acquisition of Singular Genomics (公布2024十二月24号).
- Aadi Bioscience 刚刚宣布为 100 筹款数百万美元。 (公布2024十二月20号).
生物技术 行业的其他推荐联系人
消息
Crispr Therapeutics 的最新新闻稿
- Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress | CRISPR Therapeutics
- CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress | CRISPR Therapeutics
- CRISPR Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference | CRISPR Therapeutics
- Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress | CRISPR Therapeutics
- CRISPR Therapeutics to Host Innovation Day on June 21, 2022 | CRISPR Therapeutics
- CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell Malignancies | CRISPR Therapeutics
- CRISPR Therapeutics Congratulates Co-Founder Emmanuelle Charpentier on Receiving the 2020 Nobel Prize in Chemistry | CRISPR Therapeutics
- CRISPR Therapeutics to Participate in Upcoming Investor Conferences | CRISPR Therapeutics
- CRISPR Therapeutics and Vertex Pharmaceuticals Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to CTX001™ for the Treatment of Sickle Cell Disease | CRISPR Therapeutics
- CRISPR Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference | CRISPR Therapeutics
- View more press releases Close
通过电子邮件
